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This paper compiles the beneficial eﬀects of cocoa polyphenols on human health, especially with regard to cardiovascular and
inflammatory diseases, metabolic disorders, and cancer prevention. Their antioxidant properties may be responsible for many
of their pharmacological eﬀects, including the inhibition of lipid peroxidation and the protection of LDL-cholesterol against
oxidation, and increase resistance to oxidative stress. The phenolics from cocoa also modify the glycemic response and the lipid
profile, decreasing platelet function and inflammation along with diastolic and systolic arterial pressures, which, taken together,
may reduce the risk of cardiovascular mortality. Cocoa polyphenols can also modulate intestinal inflammation through the
reduction of neutrophil infiltration and expression of diﬀerent transcription factors, which leads to decreases in the production of
proinflammatory enzymes and cytokines. The phenolics from cocoa may thus protect against diseases in which oxidative stress is
implicated as a causal or contributing factor, such as cancer. They also have antiproliferative, antimutagenic, and chemoprotective
eﬀects, in addition to their anticariogenic eﬀects.
1. Introduction
Plant phenols from numerous plant species are being actively
studied as potential treatments for various metabolic and
cardiovascular diseases. For example, resveratrol from red
wine [1, 2], epigallocathechin-3-gallate from green tea [3–
5], curcumin from turmeric [6], and quercetin [7–12] from
diﬀerent sources have all been studied as potential thera-
peutic agents, to induce weight loss, lower blood pressure,
attenuate glucose levels and insulin resistance (resveratrol),
and improve hemoglobin A1c and lipid profile in humans
(epigallocathechin-3-gallate). Other studies also carried out
in humans have shown the beneficial eﬀects of grape seeds,
chokeberries, coﬀee, carob, and cocoa [13]. This paper
reviews the most recent research on this last substance and
its potential benefits for human health.
Since the seventeenth century, cocoa and chocolate have
been described as potential medicines. In Europe, various
historical documents refer to chocolate’s medicinal value;
thus, although it was drunk as a beverage with a pleasurable
taste, it was primarily eaten as a food to treat a number of
disorders, including angina and heart pain [14]. Today, Theo-
broma cacao L. (Sterculiaceae) and its products are consumed
worldwide and are studied mainly because of the antiox-
idant and antiradical properties in vitro of some of their
polyphenolic constituents, specially procyanidins and flavan-
3-ols [15]. Many studies have described cocoa phenolics as
being bioactive compounds, especially prominent for their
metabolic and cardiovascular eﬀects. These eﬀects are due,
in part, to the antioxidant [16] and antiradical properties
of cocoa phenolics [17], which increase the plasma level
of antioxidants to prevent the oxidation of LDL-cholesterol
[18]. Along with their known antiplatelet eﬀects [19], these
particular properties are related to the protective mechanism
of cocoa phenolics in heart disease [18]. Other relevant
properties include their ability to modulate the immune
response [20–24] and their anti-inflammatory [25–27] and
anticarcinogenic properties [26, 28]. In this paper, we
have focused on the beneficial eﬀects of cocoa polyphenols
on human health, especially with regard to cardiovascular
and inflammatory diseases, metabolic disorders, and cancer
prevention as well as on their antioxidant properties.
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2. Polyphenols Content in Cocoa
Cocoa contains about 380 known chemicals, 10 of which are
psychoactive compounds. In their natural state, cocoa beans
are virtually inedible because of their high concentration of
polyphenols, which gives them an extremely bitter flavor.
In a final cocoa product such as chocolate, polyphenol
content might decrease from 100% to 10% throughout
the diﬀerent manufacturing processes [29]. For this reason,
various authors have focused on the eﬀects of polyphenol-
enriched extracts from cocoa [27, 30–32].
Wollgast and Anklam [15] reviewed the polyphenol
content of cocoa depending on its origin and the man-
ufacturing process of the final product. Three groups of
polyphenols can be identified in cocoa beans: catechins,
which constitute about 37% of the polyphenol content
in the beans, anthocyanidins (about 4%), and proantho-
cyanidins (about 58%). Of the catechins, (−)-epicatechin
is the most abundant (up to 35%), while (+)-catechin,
(+)-gallocatechin, and (−)-epigallocatechin are present in
smaller quantities (Figure 1). In the case of anthocyanidins,
the main compounds are cyanidin-3-α-L-arabinoside and
cyanidin-3-β-D-galactoside, while in the case of procyani-
dins, the main compounds are dimers, trimers, or oligomers
of flavan-3,4-diol linked by 4 → 8 or 4 → 6 bonds.
Of these, the main procyanidins are B1, B2, B3, B4, B5,
C1, and D. The proportions of these derivatives usually
change during the manufacturing process. For example,
in the dried, fat-free mass of fresh cocoa beans, the total
soluble polyphenol content is 15–20%, which is equivalent
to 6% in air-dried, nondefatted cocoa beans. In contrast, it
is only about 5% in fermented, nondefatted beans because
during the fermentation process epicatechin and soluble
polyphenol content is reduced by approximately 10 to 20%,
anthocyanidins disappear, and procyanidins decrease 3- to 5-
fold. There is also a great amount of variation in the phenolic
content of cocoa depending on its origin. For example, (−)-
catechin concentration in fermented, defatted cocoa beans
varies from 16.52mg/g in Costa Rican cocoa to 2.66mg/g in
cocoa grown in Jamaica.
3. Bioavailability of Phenolics from Cocoa
There is a great controversy surrounding the bioavailability
of phenolics in general and of cocoa derivatives in par-
ticular. For example, epicatechin is well absorbed, with a
maximum plasma concentration at around 2 h and with
approximately 20% of consumed epicatechin being excreted
in the urine [33]. In the case of dimers, their presence has
been also described in plasma. For example, Holt et al.
[34] described the presence of procyanidin dimers, especially
B2 (epicatechin-(4β-8)-epicatechin) in peripheral blood of
healthy adults who had consumed a cocoa beverage.
3.1. Gastric Degradation of Cocoa Phenolics. There have
been contradictory findings concerning the gastric stability
of phenols from cocoa. For example, Spencer et al. [35]
reported that, in the acidic environment of the gastric
milieu, procyanidin oligomers are hydrolyzed to mixtures
of epicatechin monomers and dimers. However, Rios et
al. [36] observed that, during gastric transit, procyanidins
were remarkably stable in the stomach environment and
reached the small intestine intact, available for absorption
or metabolism. In addition, their limited absorption in the
small intestine could influence the digestive process or the
physiology of the gut through direct interaction with the
gut mucosa and gut lumen solutes. Consequently, some
of the health eﬀects of procyanidins may be associated
with the formation by microflora of low-molecular-weight
metabolites once the procyanidins reach the colon. This
hypothesis has been corroborated by Gonthier et al. [37],
who demonstrated that while proanthocyanidins of high
molecular weight are not present in plasma or urine,
the monomers and aromatic acids produced during their
metabolism by intestinal microflora can be found in the
latter. These researchers also demonstrated that catechin is
well absorbed in the small intestine, with recoveries of 20–
40%.
3.2. Intestinal Absorption of Phenols from Cocoa. Ortega et al.
[38] coupled an in vitro digestionmethod with a continuous-
flow dialyzed duodenal step to construct a model for exam-
ining the digestibility and bioaccessibility of polyphenols in
cocoa food matrices. Their results show that the fat content
of the cocoa samples tested enhances the digestibility of
some phenolic compounds, especially procyanidins, during
duodenal digestion. The possible mechanism is probably
related to the fat fraction’s ability to interact with certain
phenol compounds following a better micellization of the
digested phenols.
A human bioavailability trial with chocolate polyphenols
using 40 g of dark chocolate (892mg of total polyphenols
expressed as gallic acid equivalent and 82mg of epicatechin)
showed that epicatechin was indeed absorbed into the blood.
The compound was detectable in plasma as glucuronide-
conjugated metabolites and sulfate groups after 2 h and was
still present after 8 h. The clearance of epicatechin from the
plasma compartment was very fast, with an elimination t1/2
of 1.9 and 2.3 h for 40 and 80 g of chocolate, respectively [29].
Manach et al. [39] found that the metabolism of simple
phenols occurs via a common pathway, being absorbed in the
small intestine, and oligomers larger than trimers are unlikely
to be absorbed in the small intestine in their native forms.
In vitro experiments using single layers of Caco-2 cells as a
model of absorption in the small intestine have corroborated
the in vivo studies because they showed that only the dimers
and trimers of flavan-3-ols are able to cross the intestinal
epithelium; thus, procyanidin B2 is poorly absorbed in rats
whereas procyanidin B3 is not absorbed at all [39].
In a study on the bioavailability of cocoa polyphenols in
healthy volunteers, Toma´s-Barbera´n et al. [30] demonstrated
that the flavonoid composition (mainly flavanol monomers
and dimers) of cocoa powder can be enhanced through
improved processing of the raw material and that these
flavanol-enriched samples lead to increases in the cocoa
flavan-3-ols present in plasma and urine, thus increasing
their bioavailability.
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Figure 1: Continued.
4 Oxidative Medicine and Cellular Longevity
O
OH
HO
OH
OH
OH
OH
O
OH
OH
OH
HO
O
OH
HO
OH
OH
OH
Procyanidin C1
(i)
Figure 1: Chemical structure of major cocoa phenolics.
4. Antioxidant Properties of Cocoa Phenolics
4.1. Scavenging Activity. Cocoa has more phenolics and
higher antioxidant capacity than green tea, black tea,
or red wine. In fact, Lee et al. [40] found that cocoa
contains 611mg/serving of gallic acid equivalents and
564mg/serving of epicatechin equivalents. The values for
gallic acid equivalents were 1.8, 3.7, and 4.9 higher than
those obtained for red wine, green tea, and black tea,
respectively, while the epicatechin equivalents were 3.5, 12.0,
and 16.6, respectively, for the same beverages. The values
for antioxidant activity, measured with the aid of 2,2′-
azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS+)
and 2,2-diphenyl-1-pycrylhydrazyl (DPPH) methods, were
1128 and 836mg/serving, respectively, expressed as vitamin
C equivalent antioxidant capacity. When compared against
that of red wine, green tea, or black tea, the relative activity of
cocoa was 1.8, 2.5, and 4.4 times higher, respectively, in the
ABTS+ test, and 1.7, 2.4, and 4.3 times higher, respectively,
in the DPPH test. The authors thus concluded that on a
perserving basis, cocoa has higher flavonoid content and
antioxidant capacity than red wine (2 times), green tea (2-
3 times), and black tea (4-5 times), respectively.
Schinella et al. [16] studied the antioxidant activity
of diﬀerent cocoa extracts and demonstrated their eﬀects
on diﬀerent in vitro experimental models, proving that
the antioxidant eﬀects cannot be fully characterized with
one single method. The extracts’ scavenging capacity was
measured as the ability to bleach the stable radicals DPPH
and ABTS+, their reducing ability was assessed with the ferric
reducing-antioxidant power (FRAP) assay, and their scav-
enging properties against H2O2, HClO, and peroxynitrite
were also evaluated. The extracts acted both as a free radical
scavenger (DPPH, ABTS+, superoxide, hypochloride, and
peroxinitrite) and a lipid peroxidation inhibitor way that
was directly proportional to their polyphenol content. The
extracts also inhibited superoxide production by polymor-
phonuclear leukocytes. These findings indicate that cocoa
extracts may modify the biological functions of these cells,
which are implicated in the initiation and maintenance of
inflammation. The extracts also showed scavenging activity
against peroxynitrite, both in the presence and in the absence
of a physiological concentration of bicarbonate. Under phys-
iological conditions, bicarbonate levels are usually high and
significant amounts of nitrosoperoxycarbonate anion adduct
can be produced; however, in inflamed tissues where the pH
value is lower, diﬀerent reactions may occur independent of
the presence of CO2. Because peroxynitrite anion can attack a
wide range of biological molecules, its inhibition can provide
protection against the damage induced by this free radical.
In a previous study, Schroeder et al. [41] examined the
eﬀect of a specific cocoa flavanol, (−)-epicatechin in a cel-
lular model (murine aortic endothelial cells) for examining
its protective action against peroxynitrite eﬀects, and found
that while it eﬀectively blocked the nitration of protein tyro-
sine residues by peroxynitrite (IC50 value = approximately
0.02mol epicatechin/mol peroxynitrite), its ability to block
the oxidative inactivation of glyceraldehyde-3-phosphate
dehydrogenase or soybean lipoxygenase (LOX)-1 was not
significant (IC50 > 1mol epicatechin/mol peroxynitrite).
4.2. Lipid Peroxidation. Schinella et al. [16] evaluated the
ability of cocoa powder to bring about lipid peroxidation
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in brain homogenates and human plasma using nonen-
zymatic generation systems. Cocoa powder inhibited lipid
peroxidation in both the homogenates and the plasma but
had no eﬀect on the hydroxyl radical, nor did it exhibit
ferrous chelating activity. Metal chelating capacity reduces
the concentration of the catalyzing transition metal in
lipid peroxidation. It has previously been reported that the
chelation eﬃciency of some compounds with a phenyl group
on Fe2+ depends on the number of hydroxyl groups on the
benzene ring and that hydroxyl substitution in the ortho
position results in a higher chelating eﬀect. However, because
the polyphenol-rich cocoa extract showed neither ferrous
nor copper chelating activity, it most likely acts as a chain-
breaking antioxidant.
Verstraeten et al. [42] studied the antioxidant and mem-
brane eﬀects of procyanidin B2 (dimer) and procyanidin
C1 (trimer) from cocoa in phosphatidyl choline liposomes.
Both procyanidins inhibited lipid oxidation of liposomes in
a concentration (0.33–5 μM)-dependent manner; moreover,
both compounds also increased the membrane surface
potential. They did this by decreasing membrane fluidity,
an eﬀect that extended into the hydrophobic region of
the bilayer, protecting the lipid bilayer from disruption by
Triton X-100. Procyanidins can thus interact with membrane
phospholipids, probably through their polar head group, to
provide protection against the attack of oxidants and other
molecules that challenge the integrity of the bilayer.
4.3. Resistance to Oxidative Stress. Martorell et al. [43] used
model organisms to study the eﬀect of cocoa polyphenols on
resistance to oxidative stress. A protocol of acute oxidative
stress was optimized in order to test the best conditions to
induce oxidative damage in Saccharomyces cerevisiae: doses
of 4mg/mL of a polyphenol-enriched cocoa powder led
to an increased resistance to hydrogen peroxide (2 and
3mM) tolerance, similar to those observed in cells treated
with vitamin C. To discard the possibility that this was a
strain-related eﬀect, the authors repeated the test with other
strains belonging to S. cerevisiae species. To discover the
metabolic target with which the polyphenol-enriched cocoa
powder might interact, authors evaluated the transcriptional
profile concluding that the protection upon oxidative stress is
mediated at least by sirtuins in S. cerevisiae. In order to clarify
the function of sirtuin proteins as metabolic targets of cocoa
flavonoids, diﬀerent trials were performed with a more com-
plex model, the nematode Caenorhabditis elegans. Worms
fed with the cocoa powder were more resistant toward the
oxidative stressor hydrogen peroxide, increasing their sur-
vival rate from 36% to 53% and their lifespan in a 17% after
being fed with the cocoa powder. However, mutant strains of
the worm for sirtuin and for the transcription factor DAF-
1 did not show resistance to oxidative stress nor prolonged
lifespan, suggesting that the eﬀects of cocoa powder are
mediated at least through these genes. This work highlights
the potential of polyphenol-enriched cocoa powder as a
functional ingredient with resistance to oxidative stress.
In a clinical study, Spadafranca et al. [44] investigated
the eﬀects of both dark chocolate (860mg of polyphenols,
of which 58mg were epicatechin) and white chocolate
(5mg of polyphenols, undetectable epicatechin) on plasma
epicatechin levels, DNA damage to mononuclear blood
cells, and total plasma antioxidant activity in 20 healthy
subjects who followed a balanced diet for 4 weeks. Detectable
epicatechin levels were only observed 2 h after dark chocolate
intake, at which timeless DNA damage to mononuclear
blood cells was likewise observed, but both eﬀects were
no longer evident after 22 h. No eﬀect on total plasma
antioxidant activity was noted. These results demonstrate
that dark chocolate improves DNA resistance to oxidative
stress in healthy subjects but that this eﬀect is transient,
probably due to flavonoid kinetics. Because oxidative stress
not only aﬀects both the inflammatory process and athero-
genesis, but also has mutagenic power over the human
genome, the protective eﬀect of cocoa polyphenols may have
important consequences for oncogene expression and cancer
pathogenesis.
5. Phenolics from Cocoa in Metabolic and
Endocrine Disorders
Cocoa extracts and cocoa procyanidins are potent inhibitors
of key enzymes in the digestion of carbohydrates and lipids;
these inhibitory activities are related not only to their
polyphenol content, but also to the degree of polymerization
of cocoa procyanidins, all of which are dramatically aﬀected
by the cocoa processing. For example, Gu et al. [45] assessed
their inhibitory eﬀects of diﬀerent cocoa extracts against
pancreatic α-amylase, pancreatic lipase, and secreted phos-
pholipase A2 (PLA2) in vitro and characterized the kinetics
of this inhibition and demonstrated that cocoa extracts and
the procyanidins found in them dose-dependently inhibited
all three enzymes. They also observed that the inhibitory
potency of cocoa procyanidins increases as a function of their
degree of polymerization, but they did not examine whether
cocoa extracts and/or cocoa procyanidins can inhibit diges-
tive enzymes in vivo and aﬀect related downstream pathways
such as aberrant eicosanoid metabolism at dose levels
achievable in the diet.
The principal aspects to be treated in this section are the
eﬀects of cocoa polyphenols on carbohydrate and lipoprotein
metabolism.
5.1. Eﬀects on Carbohydrate Metabolism. Hanhineva et al.
[46] published an interesting review compiling the eﬀect
of diﬀerent polyphenols, including flavonoids and proan-
thocyanidins, on carbohydrate metabolism at many levels.
In animal models and in a limited number of human
studies, polyphenols have been found to attenuate post-
prandial glycemic responses and fasting hyperglycemia while
improving acute insulin secretion and insulin sensitivity.
The possible mechanisms of action include inhibition of
carbohydrate digestion and glucose absorption in the intes-
tine, stimulation of insulin secretion from the pancreatic β-
cells, modulation of glucose release from the liver, activation
of insulin receptors and glucose uptake in the insulin-
sensitive tissues, and modulation of intracellular signaling
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pathways and gene expression. These positive eﬀects on
glucose homeostasis are also supported by epidemiological
evidence on polyphenol-rich diets.
Grassi et al. [47] compared the eﬀects of flavanol-rich
dark chocolate and flavanol-free white chocolate with regard
to endothelial function, insulin sensitivity, β-cell function,
and blood pressure in a randomized crossover trial with
19 hypertensive patients with impaired glucose tolerance.
The group of patients treated with flavanol-rich dark
chocolate (100 g/day for 15 days) showed decreased insulin
resistance and increased insulin sensitivity and β-cell func-
tion. Moreover, subjects taking flavanol-rich dark chocolate
experienced decreases in systolic and diastolic blood pres-
sure, increased flow-mediated dilation, and decreased total
cholesterol and LDL-cholesterol with respect to the control
group [47].
Similar eﬀects were described by other authors when
reviewing systematically the eﬀect of cocoa polyphenols on
cardiovascular risk factors. Shrime et al. [48] did a systematic
review and meta-analysis of randomized, controlled trials
to evaluate the eﬀect of a flavonoid-rich cocoa fraction
on cardiovascular risk factors and showed that the cocoa
phenolics decreased insulin resistance and increased flow-
mediated vascular dilation, with a maximum eﬀect observed
at a flavonoid dose of 500mg/d.
Hooper et al. [49] in a systematic review of 42 acute or
short-term chronic randomized controlled trials including
1297 patients demonstrated a significant reduction of dif-
ferent negative biomarkers of cardiovascular disease, such
as insulin resistance. Some parameters were improved in
patients after chronic and acute intake of chocolate or cocoa,
with significant reductions in serum insulin, and in flow-
mediated dilatation. In addition, the reductions in diastolic
blood pressure and mean arterial pressure were observed, as
well as a slight but significant reduction of LDL-cholesterol
and an increase of HDL-cholesterol levels. These eﬀects will
be reviewed in the following sections.
5.2. Eﬀects on Lipoprotein Metabolism. Cocoa phenolics
increase apolipoprotein (Apo) A1 and decrease ApoB pro-
duction in both the human hepatoma cell line HepG2
and the human intestinal cell line Caco2. Cells incubated
for 24 h in the presence of cocoa polyphenols such as
(−)-epicatechin, (+)-catechin, procyanidin B2, procyanidin
C1, and cinnamtannin A2 at 10 μM increased both ApoA1
protein levels and mRNA expression, even though ApoB
protein and mRNA expression decreased slightly. These
eﬀects were the result of the upregulation of the mature
form of sterol regulatory element binding proteins (SREBPs)
and increased LDL receptor activity induced by the cocoa
polyphenols. As cholesterol metabolism is known to be reg-
ulated by several diﬀerent mechanisms, it was hypothesized
that cocoa polyphenols, like other plant polyphenols, may
act via multiple pathways as a regulatory receptor agonist or
ligand. The mechanism responsible for the increase in high-
density lipoprotein (HDL)-cholesterol associated with daily
cocoa intake was also identified [50]. However, other authors
have obtained somewhat contradictory results in clinical
trials. Khan et al. [51] had previously evaluated the eﬀects
of chronic cocoa consumption (42 g/day for 4 weeks) on
lipid profile, oxidized LDL particles, and plasma antioxidant
vitamin concentrations in 42 high-risk volunteers in a ran-
domized, crossover feeding trial. The analysis of 24 h urine
revealed significant increases of phase II metabolites, includ-
ing glucuronide and sulfate conjugates. The concentration of
HDL-cholesterol was significantly higher after cocoa intake
in comparison with the control group, which received only
milk, while the oxidized LDL levels decreased. No signif-
icant changes were registered for total plasma cholesterol,
triglycerides, LDL-cholesterol, ApoA1 and ApoB, lipoprotein
concentrations, or the LDL/HDL-cholesterol ratio. Other
biochemical parameters such as fibrinogen and homocys-
teine did not vary, and no significant changes were found in
the plasma concentrations of vitamins B1, B6, B12, C, and E,
or in plasma and intraerythrocyte folic acid concentrations.
The authors studied the correlation between changes in
polyphenols, lipids, and oxidized LDL measurements and
observed higher increments in the urinary excretion of cocoa
(−)-epicatechin metabolites. Regarding cocoa metabolites
derived from intestinal microbial metabolism, an increase in
the urinary excretion of 3-hydroxyphenylacetic and vanillic
acids was observed in parallel with a significant increase
in plasma HDL-cholesterol concentration and a decrease in
plasma-oxidized LDL levels.
Jia et al. [52] studied the eﬀect of cocoa on total
cholesterol, LDL-cholesterol, and HDL-cholesterol in 8
trials involving 215 participants. Whereas LDL-cholesterol
was significantly lowered and total cholesterol marginally
lowered, no significant changes in HDL-cholesterol were
observed after cocoa consumption. There was no evidence
of a dose-eﬀect relationship, of any eﬀect in healthy subjects,
or of any change in HDL-cholesterol. The authors concluded
that short-term cocoa consumption significantly reduced
blood cholesterol, but the changes depended on the amount
of cocoa consumed and the health status of participants;
indeed, there was no dose response and no eﬀect in healthy
participants. To assess the dose-response eﬀect, Almoosawi
et al. [53] carried out a randomized, single-blind, crossover
study in which 14 overweight/obese subjects were random-
ized to take either 20 g of dark chocolate with 500mg of
polyphenols and then 20 g of dark chocolate with 1000mg
of polyphenols or vice versa. Participants followed each diet
for 2 weeks separated by a 1-week washout period.
Mellor et al. [31] conducted a randomized, placebo-
controlled double-blind crossover trial comparing the eﬀects
of chocolate with high polyphenol content (16.6mg of
epicatechins in 45 g of chocolate) with those of chocolate
with low-polyphenol content (<2mg of epicatechins in 45 g
of chocolate) on lipid profiles, weight, and glycemic control
in 12 individuals with type 2 diabetes on stable medication.
HDL-cholesterol increased significantly with high polyphe-
nol chocolate, with a decrease in the total cholesterol/HDL
ratio and no changes in any of the other parameters
under study. The authors concluded that high-polyphenol
chocolate is eﬀective in improving the atherosclerotic choles-
terol profile in patients with diabetes by increasing HDL-
cholesterol and improving the cholesterol/HDL ratio without
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aﬀecting weight, inflammatory markers, insulin resistance,
or glycemic control. However, as stated above, marginally
significant eﬀects on LDL- and HDL-cholesterol were found
by Hooper et al. [49], although there were no significant
eﬀects on total cholesterol, after acute or chronic intake. As a
secondary analysis, they assessed the eﬀects on body weight,
body mass index, and waist circumference, but few trials
reported these outcomes.
Some of these indices were recently evaluated by Shrime
et al. [48] who studied the cardioprotective eﬀects of a
flavonoid-rich cocoa fraction. The most relevant risk factors
evaluated were blood pressure, pulse, total cholesterol,
HDL-cholesterol, LDL-cholesterol, triglycerides, body mass
index, C-reactive protein, flow-mediated vascular dilation
(FMD), fasting glucose, fasting insulin, serum isoprostane,
and insulin sensitivity/resistance indices. Results showed
that LDL-cholesterol decreased by 0.077mmol/L, and HDL-
cholesterol increased by 0.046mmol/L, whereas total choles-
terol, triglycerides, and C-reactive protein remained the
same.
6. Phenolics from Cocoa in
Cardiovascular Diseases
Epidemiological studies demonstrate that regular dietary
intake of cocoa polyphenols reduces the risk of coronary
heart disease and stroke and is inversely associated with
the risk of cardiovascular disease. This eﬀect was described
for first time in the Kuna Indians (Panama), who belong
to one of the few cultures protected against the age-
dependent increase in blood pressure and the development
of arterial hypertension. These healthy eﬀects have been
correlated with the consumption of high amounts of cocoa.
Clinical studies revealed that, compared with other Pan-
American citizens, the Kunas have lower blood pressure rates
and lower mortality resulting from cardiovascular events
[54].
6.1. Eﬀects on Arachidonic Acid Metabolism. The con-
sumption of cocoa/chocolate increases plasma antioxidant
capacity, diminishes platelet function and inflammation,
and decreases diastolic and systolic arterial pressures. Cur-
rently available data indicate that daily consumption of
cocoa-rich chocolate or polyphenol-enriched cocoa extracts
could partially lower cardiovascular disease risk [55, 56].
The mechanism by which the cardiovascular protection
of cocoa polyphenols develops is complex, with diﬀer-
ent mediators and agents being implicated. For exam-
ple, the eﬀects of cocoa polyphenols on inflammatory
mediators such as leukotrienes (LT), nitric oxide (NO)
metabolism, and myeloperoxidase- (MPO-) induced mod-
ification of LDL indicate that the antioxidant properties
of polyphenol-enriched cocoa extracts could be of great
interest for developing therapies to prevent cardiovascular
disease since oxidative modification of LDL appears to
be crucial for atherogenesis. In fact, cocoa polyphenols
decrease the plasma concentration of proinflammatory
cysteinyl leukotrienes through inhibition of 5-LOX, as
demonstrated by Sies et al. [57] in isolated recombinant
human 5-LOX (IC50 of (–)-epicatechin = 22 μM). Recombi-
nant human platelet 12-LOX, a representative of another
subfamily of mammalian lipoxygenases, also was inhibited
by (–)-epicatechin (IC50 = 15 μM), therefore concluding
that this compound and related flavan-3-ols are general
inhibitors of mammalian LOX. The inhibition of human
5-LOX by cocoa flavonoids suggests that these compounds
exert antileukotriene actions, which may confer a degree
of anti-inflammatory, vasoprotective, and antibronchocon-
strictory capacity because the principal metabolite of 5-
LOX, LTB4, causes neutrophils to adhere to endothelial cells,
thus acting as a potent chemotactic agent for these and
other inflammatory cells. It also stimulates the release of
lysosomal enzymes and the generation of superoxide anion
in neutrophils, while the cysteinyl-LTs increase vascular
permeability and contract airway smooth muscle.
Another oxidant enzyme with pronounced eﬀects on
inflammation and atherogenesis is MPO, which has also been
reported to act as an NO oxidase. In vitro, MPO is capable
of binding to LDL, catalyzing oxidative modification and
rendering it atherogenic. (–)-epicatechin and procyanidins
have been shown to block the MPO/nitrite-mediated and
peroxynitrite-mediated lipid peroxidation of LDL; for exam-
ple, (–)-epicatechin is able to suppress it at concentrations as
low as 0.1 μmol/L [58].
Unlike 5-LOX and platelet-type 12-LOX, the reticulo-
cyte-type lipoxygenases (12-LOX and 15-LOX) are catalysts
of enzymatic lipid peroxidation. Oxidative modification of
LDL by 15-LOX-1, MPO, and peroxynitrite renders its
atherogenicity and plays a relevant role in the early develop-
mental stages of atherosclerotic lesions. Agents such as cocoa
polyphenols that interfere with the oxidative modification of
LDL should therefore be protective for vascular endothelium,
including that of coronary arteries.
In conclusion, the inhibitory eﬀects of cocoa polyphenols
on 5-LOX and 15-LOX-1 may contribute to their beneficial
actions [57].
6.2. Eﬀects on NO Bioactivity. Cocoa phenols also promote
the bioactivity of NO in vivo, which is critical for protecting
the cardiovascular system. Sies et al. [57] compared the
eﬀects of cocoa beverages containing diﬀerent contents of
flavanols among selected volunteers, concluding that inges-
tion of flavanol-rich cocoa by individuals with diminished
endothelial function led to an increase in the plasmaNO con-
centration approaching the mean concentrations of healthy
control subjects and doubled flow-mediated dilation after
2 h. Plasma concentrations of NO were correlated with flow-
mediated dilation, which suggests that the improvement
of endothelial function might be attributable to increased
bioavailability of NO. In contrast, these changes did not
occur among individuals who received either water or a
low-flavanol cocoa drink, which excluded eﬀects of beverage
constituents other than flavanols. The NO-promoting eﬀects
of cocoa polyphenols may also contribute to a decrease in
blood pressure because they interfere with NO metabolism
at several levels. They especially favor the synthesis of NO
8 Oxidative Medicine and Cellular Longevity
and suppress deleterious metabolites such as superoxide,
peroxynitrite, and NO2 [57].
As Corti et al. [54] cite, these compounds also induce
NO-dependent vasodilation in the rat aorta and in the finger
or forearm circulation of healthy humans or patients with
cardiovascular risk factors. Cocoa lowers vascular arginase
activity in human endothelial cells, augmenting local levels
of L-arginine, which is then transformed into NO by
endothelial nitric oxide synthase (eNOS). Once released,
NO increases intracellular cyclic guanosine monophosphate
(cGMP) concentrations, inducing a relaxation of vascular
smooth muscle cells. NO not only leads to vasodilata-
tion, but also prevents leukocyte adhesion and migration,
smooth muscle cell proliferation, and platelet adhesion
and aggregation. In patients with cardiovascular risk fac-
tors, including smoking, a cocoa drink high in flavonol
content rapidly enhances the circulating pool of bioactive
NO and augments flow-mediated vasodilation. Moreover,
chronic consumption of a high-flavanol diet is associated
with high urinary excretion of NO metabolites, which is
consistent with augmented NO production or diminished
degradation. Moreover, flavonoid-enriched cocoa results in
regional changes in cerebral blood flow and an overall
increased blood flow. In elderly humans on a high-flavanol
diet, cerebral blood flow velocity in the middle cerebral
artery has been shown to increase, suggesting that cocoa
flavanols may protect against dementia and stroke [54]. The
improvement of endothelial function is probably one of
the mechanisms by which polyphenols confer cardiovascular
protection. Indeed, polyphenols are able to induce NO-
mediated, endothelium-dependent relaxations in a large
number of arteries, including the coronary artery. In some
arteries they can also induce endothelium-derived hyperpo-
larizing factor (EDHF)-mediated relaxations. Taken together,
these mechanisms may help explain the antihypertensive and
cardioprotective eﬀects of polyphenols in vivo [58].
6.3. Eﬀects of Cocoa Phenolics on Other Mediators Impli-
cated in Vascular Properties. Cocoa procyanidins are potent
inhibitors of mitogen-activated protein kinase kinase (MEK)
and membrane type-1 (MT1)-matrix metalloproteinase
(MMP). They subsequently inhibit the expression and acti-
vation of pro-MMP-2 as well as the invasion and migration
of human vascular smooth muscle cells (VSMCs). In fact,
both cocoa procyanidin fraction (3 μg/mL) and procyanidin
B2 (5 μM) were found to strongly inhibit the thrombin-
induced activation and expression of pro-MMP-2 in VSMCs,
the thrombin-induced invasion and migration of VSMCs,
MT1-MMP activity, and the thrombin-induced phosphory-
lation of extracellular signal-regulated protein kinase (ERK)
(but not that of MEK) in VSMCs. Kinase and pull-down
data show that cocoa procyanidin fraction and procyanidin
B2 inhibit MEK1 activity, binding directly with glutathione-
S-transferase-MEK1. These results may partially explain the
molecular action of cocoa’s antiatherosclerotic eﬀects [59].
There is evidence of the structure-activity relationship of
endothelium-dependent vasodilator responses to procyani-
dins in isolated vessels. This is consistent with the hypothesis
that these responses are mediated by a procyanidin receptor,
which could represent an important target for new agents to
treat endothelial dysfunction. Because this response involves
signaling through superoxide or hydrogen peroxide, it could
even be considered prooxidant. Flow-mediated dilatation
also involves signaling through hydrogen peroxide. Hence,
these findings bolster the hypothesis that procyanidins
trigger an endothelial response similar to that of laminar
shear stress [60].
In a controlled trial, Monagas et al. [32] evaluated
the eﬀects of chronic cocoa consumption on cellular and
serum biomarkers related to atherosclerosis in 42 high-risk
patients in a randomized crossover feeding trial. All subjects
received 40 g cocoa powder with 500mL skim milk per
day or only 500mL skim milk per day for 4 weeks. No
significant changes in the expression of adhesion molecules
on T lymphocyte surfaces were observed. However, in
monocytes, the expression of VLA-4, CD40, and CD36 was
significantly lower in the cocoa intake group compared to
the control group. In addition, serum concentrations of the
soluble endothelium-derived adhesion molecule P-selectin
and intercellular adhesion molecule (ICAM)-1 were signif-
icantly lower after cocoa intake than after milk intake. The
authors concluded that the intake of cocoa polyphenols may
modulate inflammatory mediators in patients at high risk
for cardiovascular disease; indeed, these anti-inflammatory
eﬀects may contribute to the overall benefits of cocoa
consumption against atherosclerosis.
The vascular actions associated with transforming
growth factor (TGF)-β1 and homeostatic modulation of its
production by flavan-3-ols and procyanidins from cocoa
may constitute another mechanism by which phenolics from
cocoa can potentially benefit cardiovascular health. In this
context, Mao et al. [61] studied the eﬀect of flavan-3-ols
and procyanidins fractions (monomers through decamers)
isolated from cocoa on the secretion of the cytokine TGF-
β1 in resting human peripheral blood mononuclear cells
(PBMCs) from 13 healthy subjects. When cells of individuals
with low baseline levels of TGF-β1 were stimulated by
individual flavan-3-ol and procyanidin fractions (25 μg/mL),
TGF-β1 release was enhanced in the range of 16–66%. The
low-molecular-weight fractions (≤pentamers) were more
eﬀective at augmenting TGF-β1 secretion than their larger
counterparts (hexamer or higher), with the monomer and
dimer inducing the greatest increases (66% and 68%, resp.).
In contrast, in the case high TGF-β1 baseline subjects, the
TGF-β1 secretion was inhibited, being the inhibition most
pronounced for trimmers through decamers (28–42%, resp.)
and moderate for monomers to dimers (17–23%, resp.).
Given the vascular actions associated with TGF-β1 release,
this homeostatic modulation by cocoa polyphenols oﬀers an
additional mechanism by which polyphenol-rich foods can
benefit cardiovascular health.
6.4. Cocoa Phenols and Cardiovascular Disease. Ding et al.
[62] carried out a systematic review of experimental, obser-
vational, and clinical studies of the relationship between
chocolate and cocoa and the risk of cardiovascular disease.
The data from a total of 136 publications suggests that
cocoa and chocolate may exert beneficial eﬀects with regard
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to cardiovascular risk via various mechanisms, including
lowering blood pressure, anti-inflammation, anti-platelet
function, increasing HDL level while decreasing LDL oxida-
tion. In addition, prospective studies of flavonoids suggest
that the phenolic content of chocolate may reduce the risk of
cardiovascular mortality.
Phenolics from cocoa also decrease the tendency of
blood to clot. For example, an acute dose of flavanols
and oligomeric procyanidins from cocoa powder was found
to inhibit platelet activation and function for over 6 h
in humans. In a blinded parallel-design study, 32 healthy
subjects were assigned to consume 234mg cocoa phenolics
a day [63].
6.5. Eﬀects on Platelet Function. Platelet function was deter-
mined by measuring platelet aggregation, ATP release, and
the expression of activation-dependent platelet antigens.
After 28 days of treatment, cocoa polyphenol supplemen-
tation increased plasma epicatechin and catechin concen-
trations by 81% and 28%, respectively, while decreasing
platelet function. These findings are in agreement with
results from studies that used higher doses of cocoa flavanols
and procyanidins [63]. Moreover, cocoa decreases not only
platelet aggregation, but also adhesion. The eﬀects of cocoa
polyphenols could thus be explained in part by their ability
to reduce the ADP-induced expression of the activated
conformation of glycoprotein IIb/IIIa surface proteins [54].
Various studies have indicated that dark chocolate induces
coronary vasodilation, improves coronary vascular function,
and decreases platelet adhesion. These immediate beneficial
eﬀects are paralleled by a significant reduction in serum
oxidative stress and have been positively correlated with
changes in serum epicatechin concentration. Flammer et al.
[64] studied these eﬀects on coronary vascular and platelet
function in 22 heart transplant recipients in a double-
blind, randomized study. The ingestion of 40 g of flavonoid-
rich dark chocolate (containing 0.27mg/g of catechin and
0.9mg/g of epicatechin, with a total polyphenol content
of 15.6mg of epicatechin equivalents per gram) increased
coronary artery diameter, improved endothelium-dependent
coronary vasomotion, and decreased platelet adhesion, all of
which remained unchanged in the control group.
Carnevale et al. [65] carried out a crossover, single blind
study with 20 healthy subjects and 20 smokers who received
40 g of dark (cocoa > 85%) or milk (cocoa < 35%) chocolate.
Compared to healthy subjects, smokers showed enhance-
ments in platelet recruitment, platelet formation of reactive
oxygen species (ROS) and eicosanoids, and nicotinamide
adenine dinucleotide phosphate (NADPH)-reduced oxidase
(NOX)2 activation. In the dark chocolate group, platelet
ROS, 8-iso-prostaglandin (PG)F2α, and NOX2 activation
decreased significantly, but in the subgroup of healthy
subjects taking dark chocolate, platelet variables did not
change. No changes were detected in either of the groups
treated withmilk chocolate. The authors concluded that dark
chocolate inhibits platelet function by lowering oxidative
stress only in smokers; this eﬀect seems to be dependent on
its polyphenol content.
6.6. Eﬀects on Arterial Hypertension. As discussed above,
animal and human studies suggest that cocoa and choco-
late could regulate NO bioavailability, aﬀecting endothelial
function and, in turn, blood pressure. Although these studies
are not definitive and many questions remain, the body of
evidence suggests that it is worth considering diets that can
provide benefits to patients with high blood pressure; indeed,
these benefits will be more significant in subjects that do not
have their hypertension under control [66].
As mentioned above, significant reductions in diastolic
blood pressure and mean arterial pressure after chronic
intake were observed in Hooper’s review [48].
Cienfuegos-Jovellanos et al. [67] evaluated the eﬀects of
various doses of a natural flavonoid-enriched cocoa powder
(50–600mg/kg) on spontaneously hypertensive rats. The
polyphenol extract produced an antihypertensive eﬀect in
hypertensive rats without modifying the arterial blood pres-
sure in normotensive rats. However, no dose-response eﬀect
was observed: the maximum eﬀect on the systolic blood
pressure of hypertensive rats was reached with 300mg/kg
of extract, while the maximum eﬀect on the diastolic blood
pressure, was achieved with a dose of 100mg/kg. In a
complementary study, Almoosawi et al. [53] found that the
500mg polyphenol dose was equally eﬀective in reducing
systolic blood pressure, and diastolic blood pressure as the
1000mg polyphenol dose, which suggests that a saturation
eﬀect might occur with increased doses of polyphenols.
Akita et al. [68] studied the eﬀect of dietary intake of
cocoa polyphenols on heart rate, blood pressure, and plasma
lipid concentrations. The area of atherosclerotic lesions in
the aortas of the polyphenol-treated group was significantly
smaller than in the control group. In addition, whereas the
high-frequency power of heart rate variability of the rabbits
in the standard diet group decreased significantly with
ageing, there were no diﬀerences between long- and short-
term treatments in the polyphenol group. Moreover, cocoa
liquor polyphenols preserved parasympathetic nervous tone,
although this decreased significantly with ageing in the
standard diet group. No diﬀerences in the plasma lipid
concentrations were observed. The authors concluded that
cocoa liquor polyphenols may play an important role in
protecting cardiovascular function.
To date, epidemiological data on cocoa polyphenols has
been scarce. Rimbach et al. [69] reviewed diﬀerent relevant
clinical trials and selected the results of five of them in which
the following conclusions were established: in a cohort of
elderly men, cocoa intake was inversely associated with blood
pressure as well as with 15-year cardiovascular and all-cause
mortality; a prospective study examined flavonoid intake
and cardiovascular disease mortality in postmenopausal
women; a meta-analysis of 133 studies on flavonoids,
flavonoid-rich foods, and cardiovascular disease risk found
a correlation between chocolate intake and increased flow-
mediated dilation along with reductions in both systolic
and diastolic blood pressure; a cohort study involving over
1100 nondiabetic patients assessed the long-term eﬀects of
chocolate consumption amongst patients with established
coronary heart disease; finally, a study conducted with
patients surviving their first acute myocardial infarction
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found that chocolate consumption was associated with
significant reductions in cardiac mortality and beneficial
eﬀects on vascular health. However, these studies raise
many doubts. For example, the products used in controlled
studies often contain much higher polyphenol contents than
most commercially available products. It thus needs to be
established whether the consumption of products with lower
polyphenol content is associated with any health benefits in
humans. Moreover, many of these studies have mainly been
funded by industrial sponsors, and it must be remembered
that the food industry is encouraged to label the flavonoid
content on cocoa-derived products [69].
In a 6-month clinical trial carried out by Ried et al.
[70] with 36 prehypertensive healthy adult volunteers, at
content levels of 120–139 and 80–89mmHg, no significant
diﬀerences were observed in the blood pressures of the
treated and control groups. However, a marked diﬀerence
in acceptability between the two treatment forms (chocolate
or capsule) was observed due to the amount of chocolate
that had to be eaten (50 g of dark chocolate every day). In
contrast, other studies [71] have reported on blood pressure
changes in response to flavanol-rich cocoa in healthy subjects
as well as in prehypertensive and hypertensive patients, sug-
gesting that the inclusion of moderate amounts of flavanol-
rich cocoa or chocolate in the daily diet may potentially
ameliorate or delay the onset of hypertension. Indeed, it has
been estimated that a 3mmHg reduction in systolic blood
pressure reduces the relative risk of stroke mortality by 8%,
of coronary artery disease mortality by 5%, and of all-cause
mortality by 4%.
Actis-Goretta et al. [72] examined the eﬀects of diﬀerent
isolated polyphenols from cocoa on angiotensin converting
enzyme activity; several procyanidins (dimer and hexamer)
and epigallocatechin significantly inhibited the enzyme activ-
ity, whereas monomers, flavonols, phenolic acids, and resver-
atrol at similar concentrations showed no activity. Authors
established three levels of IC50: values in the mM range
for monomeric flavan-3-ols, in the 100 μM range for dimer
and trimer, and in the 10 μM range for larger procyanidins,
although these concentrations should be interpreted with
caution as they were estimated using nonphysiological in
vitro conditions. These in vitro eﬀects were correlated with
the in vivo reductions in blood pressure observed in several
experimental models [72].
Cherniack [13] reviewed the eﬀects of polyphenols on
metabolic syndrome and noted that eight patients with coro-
nary artery disease who were given cocoa drinks containing
a 375mg dose of cocoa polyphenols twice a day for 1 month
had improved vasodilatory capacity in their brachial arteries
and were able to produce larger numbers of endothelial
progenitor cells. Moreover, the systolic blood pressure of
subjects taking the larger dose cocoa decreased 4.2mmHg,
an eﬀect which was not observed in the group that consumed
only 9mg twice a day. In addition, meta-analyses of human
trials have concluded that cocoa can lower systolic and
diastolic blood pressure by 4.5 and 2.5, respectively [13].
A meta-analysis with 10 randomized controlled trials
comprising 297 individuals confirmed the blood pressure-
lowering capacity of flavanol-rich cocoa products in a larger
set of trials than previously reported. Both the systolic
and diastolic blood pressures decreased in either healthy
normotensive adults or patients with prehypertension/stage
1 hypertension. However, significant statistical heterogeneity
across studies was described [73].
In summary, critical attention must be paid to the fla-
vanol content of cocoa foods since manufacturing processes
significantly reduce its concentration in the final product.
The high fat and sugar content of many cocoa snacks and
confectionaries must also be taken into account. However,
even with these limitations, the latest findings on the eﬀects
of flavonoid-rich cocoa are of clinical relevance and hold
promise for the development of new, low calorie cocoa foods
and beverages. Further research is needed to characterize the
mechanisms of action leading to the final eﬀects of cocoa.
Also, before recommending cocoa products as a treatment
option in hypertensive and at-risk patients, well-designed,
long-term clinical trials are needed to definitively confirm
the putative beneficial role of long-term consumption of
flavanol-rich foods. Specific attention should be paid to
clarifying questions concerning the most appropriate dose,
the best targets, and eventual long-term and high-dose side
eﬀect profiles [69].
7. Effects of Cocoa Phenolics on
the Immune System
Kenny et al. [21] demonstrated that cocoa oligomers are
potent stimulators of both the innate immune system and
early events in adaptive immunity. They supported their
hypothesis with evidence that the chain length of flavanol
fractions showed a significant eﬀect on cytokine release from
both unstimulated and LPS-stimulated PBMCs after 16 h
treatment (20 μg/mL). For example, there was a marked
increase in LPS-induced synthesis of interleukin (IL)-1β, IL-
6, IL-10, and TNF-α in the presence of long-chain flavanol
fractions (hexamers to decamers). Both long- and short-
chain flavanol fractions stimulated the production of gran-
ulocyte macrophage colony-stimulating factor (GM-CSF) in
the absence of LPS and increased the expression of the B
cell markers CD69 and CD83. However, diﬀerent results
were obtained by other authors using phytohemagglutinin A
(PHA)-stimulated PBMCs, in which the production of these
cytokines depended on the degree of polymerization. For
example, IL-1β was suppressed by monomers to tetramers,
but stimulated by pentamers to decamers, and TNF-α
was clearly increased only by decamers [25]. These results
indicate that some eﬀects of cocoa polyphenols depend on
their degree of polymerization as well as the agent used for
cell stimulation.
8. Anti-Inflammatory Properties of
Phenolics from Cocoa
Sies et al. [57] reviewed the eﬀects of cocoa phenolics on
inflammatory mediators such as leukotrienes. Some of these
eﬀects have been previously cited for their implication in
cardiovascular diseases. They reported that (−)-epicatechin
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inhibits the dioxygenase and LTA2 synthase activities of
5-LOX, the first two consecutive steps in the conversion
of arachidonic acid into various proinflammatory agents,
including leukotrienes, which are catalyzed by the same
enzyme. (−)-Epicatechin has also been shown to inhibit
15-LOX-1. When other cocoa products (e.g., oligomeric
procyanidins) were tested as potential inhibitors, the authors
observed that only small procyanidins (dimers to pentamers)
showed eﬀects similar to those of monomers. However, the
pattern against 12-LOX-1 was quite diﬀerent. The inhibitory
potency first decreased from monomers to tetramers but
then increased with the oligomer size, with the decamer
being the most potent. These eﬀects were also demonstrated
in vivo. The subjects with a diet including polyphenol-rich
cocoa products had lower levels of plasma leukotrienes LTC4,
LTD4, and LTE4, along with increased levels of prostacyclin
2 h after treatment [25].
8.1. Eﬀects on Proinflammatory Cytokine Release. Ramiro
et al. [74] studied the eﬀects of a cocoa extract on the
secretion and RNA expression of various proinflammatory
mediators by macrophages. Of these, monocyte chemoat-
tractant protein (MCP)-1 and tumor necrosis factor (TNF)-
α were significantly and dose-dependently diminished by the
extract. All cocoa flavonoids tested were capable of reducing
MCP-1 secretion after 6 h of LPS activation. Thus, epicate-
chin (100−200 μM, corresponding to 29−58 μg/mL) reduced
MCP-1 secretion, exhibiting an inhibition of up to 28%;
cocoa extract (50 μg/mL) also diminished MCP-1 secretion,
and this eﬀect was significantly stronger than that produced
by epicatechin (58 μg/mL). Isoquercitrin (5−40 μM, which
represents 2.32−18.6 μg/mL) was the most eﬀective in
lowering MCP-1 levels, causing a 28−65% dose-dependent
decrease. As for TNF-α, both epicatechin (58 μg/mL) and iso-
quercitrin (18.6 μg/mL) significantly reduced TNF-α secre-
tion, achieving an inhibition of approximately 35% and
20%, respectively. Cocoa extract (50 μg/mL) also significantly
decreased TNF-α secretion by about 15%. These eﬀects may
be produced, at least in part, at the transcriptional level. A
58 μg/mL concentration of epicatechin reduced TNF-α and
IL-6 mRNA levels, having a higher eﬀect on IL-1α mRNA
expression, and one which was very close to basal levels. A
25 μg/mL concentration of cocoa extract produced a greater
downregulation of TNF-α, IL-1α, and IL-6mRNA. Following
cocoa extract treatment, IL-1α mRNA remained at basal
levels and LPS-induced TNF-α mRNA overexpression was
reduced. In addition, the extract decreased NO secretion in
a dose-dependent manner and with a greater eﬀect than that
produced by epicatechin.
There is experimental and clinical evidence that polyphe-
nols from cocoa may reduce the production of more specific
proinflammatory cytokines than those listed above, such as
IL-1β and IL-2, while stimulating the production of anti-
inflammatory cytokines such as TGF-β and IL-4. Selmi
et al. [25] reviewed the studies carried out in resting
or phytohemagglutinin A (PHA)-stimulated PBMCs. As
they recall, IL-2 production is inhibited by pentamers to
heptamers in PHA-stimulated PBMCs at mRNA level. In the
case of IL-1β, they describe the biphasic eﬀect of flavonol
fractions from monomers to tetramers, which suppressed
its mRNA expression and protein secretion, while fractions
from pentamers to decamers stimulated IL-1β production.
Similar eﬀects were observed in the case of TNF-α, which was
increased 4-fold by decameric fractions, while monomer and
dimer fractions increased TNF-α production only slightly. In
the case of the anti-inflammatory cytokine IL-4, large cocoa
flavanols fractions (pentamer through decamer) enhance
protein levels from resting PBMCs, whereas themonomers to
tetramers were not stimulatory. However, in PHA-stimulated
cells, the monomer was the only flavanol fraction able to
induce IL-4.
8.2. Eﬀects on Nuclear Factor Activation and Signal Transcrip-
tion. The regulatory eﬀects of cocoa flavanols on nuclear
factor-κB (NF-κB) activation have also been studied. (−)-
epicatechin, (+)-catechin, and their dimeric forms were
found to inhibit the NF-κB activation induced by 12-O-
tetradecanoylphorbol-13-acetate (TPA) in T cells, with a
clear reduction of NF-κB-DNA binding activity that leads
to a reduction in IL-2 production. These eﬀects were
related to direct interaction with the inhibitor of κB (IκB)
to prevent its phosphorylation, thereby preventing NF-κB
activation [25]. In a complementary study, Zhang et al. [75]
investigated the eﬀects of procyanidin dimer B2 on COX-2
expression and demonstrated that pretreatment for 30min
of diﬀerentiated human monocytic cells (THP-1) in culture
with procyanidin B2 (50 μM) reduced the LPS-induced
expression of this enzyme. This eﬀect was correlated to the
decreased activation of ERK, Jun-terminal kinase (JNK), and
p38 mitogen-activated protein kinase (MAPK), as well as to
the suppression of NF-κB activation through stabilization of
IκB proteins, which suggests that these signal-transducing
enzymes could be potential targets for procyanidin B2.
8.3. Inflammatory Bowel Disease (IBD). Various studies
conducted in both in vivo and in vitro models have provided
evidence that pure polyphenols and natural polyphenol
plant extracts can modulate intestinal inflammation. These
studies indicate that pure polyphenols and plant polyphe-
nolic extracts may play an anti-inflammatory role via the
modulation of intracellular signaling cascades in intestinal
cells. However, the number of studies on this subject is
limited and the results have been contradictory [76].
Romier-Crouzet et al. [77] studied diﬀerent polyphenol
extracts, including those from cocoa, and tested their ability
to modulate intestinal inflammation using human intestinal
Caco-2 cells treated for 4 h and stimulated with IL-1β for 24
or 48 h. Surprisingly, they found that in the absence of any
proinflammatory stimulus, the polyphenol extract of cocoa
(50 μmol of gallic acid/L) induced a basal PGE2 synthesis in
Caco-2 cells. They attributed this eﬀect to cyclooxygenase
(COX)-1 induction. However, the same extract decreased
PGE2 synthesis 4.6- and 2.2-fold in Caco-2 cells stimulated
for 24 or 48 h, respectively. As COX-1 seems to be implicated
in maintaining mucosal integrity, the induction of COX-
1 activity could be a new beneficial property of cocoa
polyphenol extract.
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A recent study performed by Andu´jar et al. [27] demon-
strated the anti-inflammatory eﬀects of a cocoa polyphenol-
enriched extract (500mg/kg) on an experimental model of
IBD. The extract was shown to reduce weight loss, improve
normal stool consistency, and reduce or eliminate visible
blood in feces in a dextran sulfate sodium (DSS)-induced
model of colitis. In parallel, it reduced neutrophil infiltration,
NO production, COX-2 expression, and expression of the
signal transducers and activators of transcription (STAT)-3
and STAT1α phosphorylation; however, the authors could
not demonstrate a clear inhibitory eﬀect on NF-κB in the
nuclear extract of the mid and distal colon. The activation
of STAT1 triggers an important signaling pathway for
many cytokine and growth factor receptors. STAT1 plays
a relevant role in IBD and especially in ulcerative colitis,
because there is an increased expression and activation of
this transcription factor in the neutrophils and monocytes
present in the intestinal lamina propria. In addition, STAT3
can be activated by diﬀerent mediators and after dimer-
ization and migration to the nucleus; it can induce the
activation of various genes, with the consequent induction
of other proinflammatory mediators. The inhibition of these
transcription factors decreases the production of COX-2, IL-
6, IL-1β, and TNF-α, which may explain the eﬀect of cocoa
polyphenol on experimental models of ulcerative colitis.
In isolated peritoneal macrophages, the authors observed
reductions in the proinflammatory cytokines IL-1β, IL-6,
and TNF-α, probably as a consequence of the inhibition
of the transcriptional factors STAT3 and STAT1α. However,
interferon (IFN)-γ was not modified. Finally, working with
LPS-stimulated RAW 264.7 cells, a reduction of nuclear p65
was observed in the NF-κB reporter gene assay.
The controversy on the eﬀects of cocoa consumption
was clarified somewhat by Va´zquez-Agell et al. [78], who
demonstrated that cocoa polyphenols reduce NF-κB activa-
tion in peripheral blood mononuclear cells in humans. They
evaluated the eﬀects of 40 g of cocoa powder with either milk
or water against those of milk alone in 18 healthy volunteers.
NF-κB activation in leukocytes and adhesion molecules
was measured before and 6 h after each intervention. The
results established that consumption of cocoa with water
significantly decreased NF-κB activation from the baseline
value. Cocoa with milk produced no change, and milk alone
led to a significant increase in NF-κB activation. The concen-
tration of soluble intercellular adhesionmolecule (sICAM)-1
significantly decreased 6 h after cocoa-water and cocoa-milk
interventions, with E-selectin decreasing only after cocoa-
water intervention. No significant changes were observed in
the concentration of soluble vascular cell adhesion molecule
(sVCAM)-1. The authors concluded that cocoa consumption
may confer beneficial anti-inflammatory eﬀects mediated by
inhibition of the NF-κB-dependent transcription pathway or
by direct interaction with certain cytokines and that the food
matrix probably plays a crucial role in the modulation of this
eﬀect.
Ingestion or systemic administration of polyphenols may
inhibit gene expression and induce phase II antioxidant and
detoxifying proteins, which may help them prevent and/or
ameliorate inflammatory colitis. Because enteral nutrition
plays an important role in the management of IBD, artificial
nutrition attempts to safely administer the essential and
otherwise beneficial constituents of food to patients with an
impaired ability to ingest or digest food; yet polyphenols
are not included in the formulae. The addition of these
compounds to artificial nutritional formulae could improve
the outcome of patients with IBD in need of enteral nutrition
[79].
9. Phenolics from Cocoa in Cancer Prevention
The antioxidant properties of cocoa or cocoa-derived prod-
ucts enriched in flavonoids may help protect against diseases
in which oxidative stress is implicated as a causal or
contributing factor. Themost relevant antioxidant properties
have been described above; the following sections are a
compilation of these eﬀects and their implications for cancer.
9.1. Cell Protection against Active Oxygen Radicals. Cocoa
liquor polyphenols could thus be therapeutically benefi-
cial, as they eﬀectively inhibit mitomycin C-induced DNA
damage and exert anticlastogenic eﬀects. Because oxidative
DNA damage seems to be implicated in mutagenesis and
carcinogenesis, the anticlastogenic activities of cocoa extract,
both through the inhibitory eﬀect of cocoa polyphenols
on the DNA strand cleavage induced by mitomycin C in
vitro and through their eﬀect against the formation of
micronuclei induced by mitomycin C in bone marrow cells
and peripheral blood cells of mice, may explain cocoa’s role
in the prevention of DNA damage, which probably occurs
through the scavenging of active oxygen radicals generated
in reactions initiated by mitomycin C [80].
Cho et al. [81] studied the protective eﬀects of a
cocoa procyanidin fraction and procyanidin B2 against the
apoptosis of PC12 rat pheochromocytoma cells induced by
hydrogen peroxide. In this case, the fraction (1 and 5 μg/mL)
and procyanidin B2 (1 and 5 μM) reduced cell death by
attenuating the hydrogen peroxide-induced fragmentation of
the nucleus and DNA in PC12 cells. Hydrogen peroxide acts
in part by inducing cleavage of poly(ADP-ribose)polymerase
(PARP) and downregulating Bcl-XL and Bcl-2 in PC12 cells,
but pretreatment with cocoa procyanidin fraction or pro-
cyanidin B2 before hydrogen peroxide treatment diminished
PARP cleavage, increased Bcl-XL and Bcl-2 expression, and
also inhibited activation of caspase-3 by hydrogen peroxide
while attenuating the phosphorylation of JNK and MAPK.
Cocoa procyanidin fraction and procyanidin B2 thus have
protective eﬀects against both hydrogen peroxide and the
oxidative stress induced by ROS, which has been strongly
associated with the pathogenesis of neurodegenerative dis-
orders, including Alzheimer’s disease. A cocoa-rich diet
also exerts antiproliferative eﬀects in azoxymethane-induced
colon cancer, decreasing ERK, protein kinase B (Akt), and
cyclin D1 levels, as demonstrated in Wistar rats. In addition,
it has proapoptotic eﬀects, as evidenced by reduced Bcl-XL
levels and increased levels of Bax and caspase-3 activity [82].
Martı´n et al. [83] studied the potential protective eﬀect
of a polyphenolic extract from cocoa on cell viability and
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the antioxidant defenses of cultured human HepG2 cells
subjected to oxidative stress by t-butyl hydroperoxide. Pre-
treatment of cells with 0.05–50 μg/mL of cocoa polyphenol
extract for 2 or 20 h completely prevented cell damage and
enhanced the activity of antioxidant enzymes. Moreover,
the lower levels of GSH caused by t-butyl hydroperoxide
in HepG2 cells were partly recovered through pretreatment
with cocoa-enriched extract, which also prevented in a
dose-dependent fashion the increase in ROS induced by t-
butyl hydroperoxide. Cocoa polyphenols thus seem to confer
significant protection against oxidation in these cells.
Cocoa polyphenol extracts dose-dependently (10–
100 μM) attenuated hydrogen peroxide-induced inhibition
of gap-junction intercellular communication (GJIC) in
rat liver epithelial (RLE) cells and inhibited the hydrogen
peroxide-induced phosphorylation and internalization of
connexin 43, which is a regulating protein of GJIC in
RLE cells. It also inhibited hydrogen peroxide-induced
accumulation of ROS and activation of ERK. However,
cocoa polyphenol extract did not block hydrogen peroxide-
induced phosphorylation of MAPK. Similar results were
observed ex vivo in RLE cell lysates in which cocoa
polyphenol extract inhibited hydrogen peroxide-induced
MAPK/MEK1 activity. In these assays cocoa polyphenol
bound directly with MEK1 to inhibit its activity. Inhibition
of GJIC is strongly involved in carcinogenesis, particularly
the tumor promotion process. Abnormal GJIC is attributable
to phosphorylation of connexin 43, which is a major protein
constituting gap-junction channels. The activation of ERK
and MAPK signaling pathways is strongly related to both
the phosphorylation of connexin 43 and the inhibition of
GJIC in RLE cells. The authors thus concluded that cocoa
polyphenols protect against hydrogen peroxide-induced
inhibition of GJIC through antioxidant activity and direct
inhibition of MEK activity, which may contribute to their
chemopreventive potential [84].
9.2. Antiproliferative Eﬀects. Treatment of cells with 50 μg/
mL of procyanidin-enriched extracts inhibited cell growth by
70%, blocking the cell cycle in the G2/M phase. The extracts
also caused a significant decrease in the activities of ornithine
decarboxylase and S-adenosylmethionine decarboxylase, two
key enzymes of polyamine biosynthesis, thus leading to a
decrease in the intracellular pool of polyamines. This could
prove to be an important target in the antiproliferative eﬀects
of cocoa polyphenols [85].
9.3. Antimutagenic and Chemoprotective Eﬀects. Ohno et
al. [86] found that cocoa extracts have an antimutagenic
eﬀect on chemical mutagens (benzo[a]pyrene) that require
metabolic activation by cytochrome P450 (CYP), specifically
CYP1A, in vitro. Cocoa products may thus prevent initiation
of cancer by inhibiting the metabolic activation of carcino-
gens by CYP1A. The authors used the Ames test to study
the eﬀects of various enriched extracts of whole cocoa prod-
ucts on the mutagenicity of benzo[a]pyrene in Salmonella
typhimurium strain TA 98 and t-butyl hydroperoxide in
S. typhimurium strain TA 102. Benzo[a]pyrene induces
mutagenicity through metabolic activation, whereas t-butyl
hydroperoxide induces it through generation of free radicals.
While white chocolate did notmodulate the number of rever-
tant colonies produced by benzo[a]pyrene treatment, milk
chocolate and cocoa powder extracts did. Surprisingly, none
of the cocoa products tested aﬀected the number of revertant
colonies produced by t-butyl hydroperoxide. Nevertheless,
at maximum concentration (13.25mg cocoa powder/mL),
the crude cocoa powder extract reduced ethoxyresorufin O-
deethylase activity to 17.4%, suggesting that whole cocoa
products inhibit CYP1A activity, which may prevent DNA
damage by reducing the metabolic activation of carcinogens.
In another study, Oleaga et al. [87] evaluated the eﬀect of
polyphenol cocoa extract in breast cancer cells (MCF-7 and
SKBR3). After incubation with 250 ng/μL of cocoa extract, 7
genes out of 84 were overexpressed and 1 was underexpressed
in MCF-7 cells, whereas 9 genes were overexpressed in
SKBR3 cells. Because CYP1A1 was expressed in both cell
lines, it was selected for further study. CYP1A1 mRNA,
protein levels, and enzymatic activity all increased upon
incubation with polyphenol cocoa extract. The combination
of polyphenol cocoa extract with tamoxifen caused a syner-
gistic cytotoxicity in both cell lines due to increased apoptosis
of MCF-7 cells. The authors concluded that the interaction
between estrogen receptor (ER)-α and aryl hydrocarbon
receptor (AhR) upon incubation with polyphenol cocoa
extract leads to the induction of CYP1A1 in breast cancer
cells. The synergy observed between polyphenol cocoa
extract and noncytotoxic tamoxifen concentrations opens
the possibility for a combination therapy in which polyphe-
nols from cocoa are used to boost the eﬃcacy of tamoxifen.
A cocoa procyanidin fraction and procyanidin B2 at
5 μg/mL and 40 μM, respectively, inhibited TPA-induced
neoplastic cell transformation of (JB6 P+) mouse epidermal
(JB6 P+) cells by 47 and 93%, respectively, through the sup-
pression of the kinase activity of MEK. They also inhibited
the expression of COX-2, the TPA-induced activation of
activator protein (AP)-1 and NF-κB, and the TPA-induced
phosphorylation of MEK, ERK, and p90 ribosomal s6 kinase,
all of which are implicated in inflammation and cancer [88].
Kim et al. [89] studied a cocoa polyphenol extract and
its eﬀect on vascular endothelial growth factor (VEGF)
expression JB6 P+ cells as well as its biological conse-
quences, including its potential eﬀects against proinflamma-
tory cytokine-mediated skin cancer and inflammation. The
cocoa polyphenol extract (5–20 μg/mL) inhibited TNF-α-
induced upregulation of VEGF by reducing TNF-α-induced
activation of the nuclear transcription factors AP-1 and NF-
κB, which are key regulators of VEGF expression. The extract
also inhibited TNF-α-induced phosphorylation of Akt and
ERK, blocked activation of their downstream kinases (p70
ribosomal protein S6 kinase and p90 ribosomal protein S6
kinase), and suppressed phosphoinositide 3-kinase (PI3 K)
activity by binding PI3 K directly. Moreover, although it did
not aﬀect the TNF-α-induced phosphorylation of MEK1,
it suppressed TNF-α-induced MEK1 activity. The direct
inhibition of PI3 K andMEK1 activities though the reduction
of TNF-α-induced upregulation of VEGF may contribute to
the chemopreventive potential of cocoa polyphenol. Indeed,
the expression of VEGF, a multifunctional cytokine that is
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a key regulator of angiogenesis, is not only associated with
tumorigenesis, but also with cardiovascular disease, rheuma-
toid arthritis, and psoriasis. Because cancerous cells require
blood vessels to increase the flow of nutrients and oxygen
vital for their development and survival via angiogenesis, the
inhibition of VEGF expression may be a promising approach
for protecting against carcinogenesis. Cocoa polyphenols
could thus be considered potential chemopreventive agents
against cancer and inflammation.
10. Phenols from Cocoa in Tooth Health
The production of caries and consumption of chocolate are
often cited in the literature, with the intake of chocolate
considered detrimental for tooth health. However, this
negative eﬀect is due to high concentrations of compounds
present in chocolate other than cocoa, such as sugar.
Ferrazzano et al. [90] were of the first to note the possible
protective eﬀect of cocoa on dental caries. Cocoa products
contain inhibitors of the dextransucrase enzyme, which is
responsible for the formation of the plaque extracellular
polysaccharides from sucrose.Moreover, phenolic substances
may be responsible for the observed anticaries eﬀect of
cocoa powder. Indeed, a water-soluble extract, of cocoa
powder was shown to significantly reduce caries scores in
rats infected with Streptococcus sobrinus, a potent cariogenic
α-haemolytic streptococcus. Complementary studies have
demonstrated that cocoa polyphenols inhibit the growth of
S. sanguinis, but not that of S. mutans. Although S. mutans
appears to be refractory to the growth-inhibitory or lethal
eﬀects of the cocoa polyphenol pentamer in routine studies,
the compound still managed to significantly inhibit acid
production from sucrose. Indeed, a recent study reports on
the use of the ground husk of cocoa beans, a by-product of
cocoa manufacture, to prepare a mouth rinse for children
that was even more eﬀective in decreasing plaque scores.
Tomofuji et al. [91] studied the potential eﬀects of
a cocoa-enriched diet (10% of the total food intake)
on gingival oxidative stress in a rat-periodontitis model
and concluded that a diet rich in cocoa could diminish
periodontitis-induced oxidative stress, which, in turn, might
suppress the progression of periodontitis. In fact, they
observed that rats with induced-experimental periodontitis
which were fed a cocoa-enriched diet did not show impair-
ments in serum reactive oxygen metabolite levels or gingival
levels for 8-hydroxydeoxyguanosine, nor did they exhibit a
reduced/oxidized glutathione ratio, as did the control group.
They proposed further studies to definitively establish the
bacterial pathogens in the periodontium and the optimum
dose of cocoa in the diet, along with new experiments
to develop an inflammatory process equivalent to chronic
periodontitis in humans.
Mao et al. [92] suggested that the consumption of some
cocoas and chocolates could reduce the risk for dental caries
and periodontal disease, justifying their hypothesis on the
basis of purified cocoa flavanol oligomers’ immunomod-
ulatory eﬀects on the in vitro production of cytokines
IL-1β, IL-2, IL-4, and IL-5. These authors established a
biphasic-type eﬀect in which the larger (hexamer through
decamer) procyanidin fractions showed more activity in
regulating cytokine production. In the case of IL-5, the
smaller procyanidin fractions (monomer through trimer)
can augment IL-5 secretion. This cytokine is implicated in
the diﬀerentiation of B cells to IgA-producing plasma cells.
IgA is considered to be protective in periodontal diseases;
therefore in this enhanced eﬀect of certain cocoa oligomer
fractions could be therapeutic for periodontal disease.
11. Other Pharmacological Effects
11.1. Antiobesity Eﬀects. Rats fed a cocoa-enriched diet
experienced a reduction in body weight, most likely due
to lower adipose tissue synthesis. Ferrazzano et al. hypoth-
esized that the polyphenols contained in cocoa may have
antiobesity eﬀects due to their ability to suppress fatty acid
synthesis while stimulating cell energy expenditure in the
mitochondria [90].
Moreover, cocoa consumption may also have beneficial
eﬀects on satiety, cognitive function, and mood [93].
11.2. Chronic Fatigue Syndrome. Sathyapalan et al. [94]
studied a polyphenol-rich chocolate and observed that it
reduced the symptoms of chronic fatigue syndrome. In fact,
in a double blind, randomized, clinical pilot crossover study
with 10 subjects, the authors compared the eﬀect of con-
suming either high cocoa liquor/polyphenol-rich chocolate
or simulated isocalorific chocolate (cocoa liquor free/low
polyphenol content) on fatigue and residual function in
subjects with chronic fatigue syndrome. After 8 weeks,
subjects in the high cocoa liquor/polyphenol-rich chocolate
group showed significant improvement as measured by
diﬀerent scoring methods, including the Chalder Fatigue
Scale and Hospital Anxiety and Depression scores, whereas
subjects taking isocalorific chocolate deteriorated.
11.3. Neurodegenerative Diseases. Bisson et al. [95] studied
and demonstrated that a cocoa polyphenol extract (Acticoa
powder) may help delay age-related brain impairments,
including cognitive deficits in normal ageing and per-
haps neurodegenerative diseases. In experiments using rats,
administration of Acticoa powder (24mg/kg/day, orally,
between 15 and 27months of age) did not show any influence
on weight or food and water consumption throughout the
study period; the benefits observed with the cocoa extract
are thus not due to dietary restriction. While the results of
this study suggest that Acticoa powder may be beneficial in
retarding age-related brain impairments, further studies are
needed to elucidate the mechanisms of cocoa polyphenols
in neuroprotection and to explore their eﬀects in man [95].
Moreover, cocoa consumption protects nerves from injury
and inflammation [93].
11.4. Antimalarial Eﬀects. Numerous anecdotal reports of
reduced episodic malaria in people from Ghana who drink
a natural, unsweetened cocoa beverage daily prompted a
search for scientific mechanisms to account for cocoa’s
possible antimalarial eﬀects. In a review of the data from
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Table 1: Eﬀects of cocoa phenolics on metabolism, cardiovascular diseases, inflammation, and cancer prevention.
(a)
Metabolic and endocrine disorders
Assays Eﬀects
In vitro
Pancreatic α-amylase, pancreatic lipase, and secreted
PLA2 inhibitions [45]
(i) Cocoa extracts and procyanidins dose-dependently
inhibited pancreatic α-amylase, pancreatic lipase, and
secreted PLA2, showing greater inhibitory activity against
PLA2. The inhibitory potency increases with the degree of
polymerization
HepG2 and Caco2 [50]
(i) (+)-catechin, (−)-epicatechin, procyanidin B2,
procyanidin C1, and cinnamtannin A2 (10 μM):
↑ ApoA1 ↓ ApoB due to upregulation of SREBPs and
increased LDL receptor activity
In vivo
Randomized crossover trial with 19 hypertensive
patients with impaired glucose tolerance [47]
(i) Flavanol-rich dark chocolate (100 g/day for 15 days):
(a) ↓ insulin resistance, systolic and diastolic blood
pressure, total cholesterol, and LDL-cholesterol
(b) ↑ insulin sensitivity, β-cell function, and
flow-mediated dilation
Randomized, crossover feeding trial in 42 high-risk
volunteers [51]
(i) Chronic cocoa consumption (42 g/day for 4 weeks):
(a) significant increases of phase II metabolites
(glucuronide, sulfate conjugates) in 24 h urine
(b) ↑HDL-cholesterol
(c) ↓ LDL-cholesterol
Meta-analysis of 8 randomized controlled trials
involving 215 participants [52]
(i) Short-term cocoa consumption:
(a) ↓ LDL and total cholesterol (changes depended on the
amount of cocoa consumed and the health status of
participants)
Randomized, single-blind, crossover study with 14
overweight/obese subjects [53]
(i) 20 g of dark chocolate with 500mg of polyphenols and
then 20 g of dark chocolate with 1000mg of polyphenols or
vice versa for 2 weeks separated by a 1-week washout period:
(a) both doses were equally eﬀective in reducing fasting
blood glucose levels, systolic blood pressure, and diastolic
blood pressure
Randomized, placebo-controlled double-blind
crossover trial [31]
(i) High polyphenol chocolate (16.6mg of epicatechins in
45 g):
(a) ↑HDL-cholesterol
(b) ↓ LDL-cholesterol, total cholesterol/HDL ratio
High-polyphenol chocolate is eﬀective in improving the
atherosclerotic cholesterol profile in patients with diabetes
(b)
Cardiovascular diseases
Assays Eﬀects
Forty-two high-risk patients in a randomized crossover
feeding trial for 4 weeks [32]
(i) 40 g of cocoa powder with 500mL skim milk/day:
(a) ↓VLA-4, CD40, and CD36 in monocytes
(b) ↓ serum concentrations of P-selectin and ICAM-1
Resting human PBMCs from 13 healthy subjects treated with
25 μg/mL of procyanidin fractions isolated from cocoa [61]
(i) Individuals with low baseline levels of TGF-β1: TGF-β1 release
was enhanced in the range of 16–66%. Low-molecular-weight
fractions (≤ pentamers) were more eﬀective than their larger
counterparts (hexamer or higher), with the monomer and dimer
inducing the greatest increases (66% and 68%, resp.)
(ii) Individuals with high baseline levels of TGF-β1: TGF-β1
secretion was inhibited, being the inhibition most pronounced for
trimmers through decamers (28–42%, resp.) and moderate for
monomers to dimers (17–23%, resp.)
Twenty healthy subjects followed a balanced diet for 4 weeks;
since day 14 to 27, they introduced daily 45 g of dark
chocolate (860mg of polyphenols, of which 58mg were
epicatechin) or white chocolate (5mg polyphenols,
undetectable epicatechin) [44]
(i) 2 h after dark chocolate intake (860mg of polyphenols, of
which 58mg were epicatechin):
(a) detectable epicatechin levels were observed
(b) less DNA damage to mononuclear blood cells
(c) no eﬀect on plasma total antioxidant activity
(ii) Eﬀects were no longer evident after 22 h: dark chocolate
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(b) Continued.
Cardiovascular diseases
Assays Eﬀects
Blinded parallel-design study with 32 healthy subjects
consuming 234mg cocoa phenolics a day for 28 days [63]
(i) ↑ Plasma epicatechin and catechin concentrations by 81% and
28%, respectively
(ii) ↓ Platelet function
Double-blind, randomized study with 22 heart transplant
recipients [64]
(i) 2 h after ingestion of 40 g of flavonoid-rich dark chocolate
(0.27mg/g of catechin and 0.9mg/g of epicatechin, with a total
polyphenol content of 15.6mg of epicatechin equivalents per
gram):
(a) ↑ coronary artery diameter
(b) improved endothelium-dependent coronary vasomotion
(c) ↓ platelet adhesion
Crossover, single blind study with 20 healthy subjects and 20
smokers who received 40 g of dark (cocoa > 85%) or milk
(cocoa < 35%) chocolate [65]
(i) Smokers:
(a) ↑ platelet recruitment, platelet formation of ROS and
eicosanoids, and NOX2 activation
(ii) Smokers + dark chocolate group:
(a) ↓ platelet ROS, PGF2α, and NOX2 activation decreased
significantly
(iii) Healthy + dark chocolate:
(a) platelet variables did not change
(iv) Milk chocolate (smokers and healthy):
(a) no changes detected in either of the groups treated with
milk chocolate
Single oral administration of a natural flavonoid-enriched
cocoa powder (50–600mg/kg) in spontaneously hypertensive
rats [67]
Antihypertensive eﬀect in hypertensive rats without modifying the
arterial blood pressure in normotensive rats. No dose-response
eﬀect was observed
Fifty male Kurosawa and Kusanagi-hypercholesterolemic
rabbits received 100 g/day of standard diet or cacao liquor
polyphenol diet [68]
(i) Polyphenol-treated group:
(a)↓ area of atherosclerotic lesions in the aortas of the
polyphenol-treated group was significantly smaller than in the
control group
(b) preserved parasympathetic nervous tone
(c) no diﬀerences in the plasma lipid concentrations
Six-month clinical trial with 36 prehypertensive healthy adult
volunteers, at content levels of 120–139 and 80–89mmHg
[70]
(i) 50 g of dark chocolate/day:
(a) no significant diﬀerences were observed in the blood
pressures of the treated and control groups
In vitro measurement of the kinetics of inhibition of purified
angiotensin I converting enzyme from rabbit lung [72]
(i) Significantly inhibited the angiotensin I converting enzyme
activity
(ii) Monomeric flavan-3-ols: IC50 in the mM range
(iii) Dimer and trimer: IC50 in the 100 μM range
(iv) Larger procyanidins: IC50 in the 10 μM range
(c)
Anti-inflammatory properties
In vitro assays Polyphenol Eﬀect
Unstimulated and
LPS-stimulated PBMCs [20]
Diﬀerent flavanol fractions (20 μg/mL)
(i) Monomers-pentamers: ↑ of LPS-induced
synthesis of IL-1β, IL-6, IL-10, and TNF-α
(ii) Long- and short-chain flavanol fractions: ↑
the production of GM-CSF in the absence of LPS
and the expression of CD69 and CD83
Macrophages [73]
(i) Epicatechin (58 μg/mL)
(ii) Cocoa extract (50 μg/mL)
(iii) Isoquercitrin (18.6 μg/mL)
(i) ↓MCP-1 and TNF-α at the transcriptional
level
(ii) ↓ TNF-α, IL-1α, and IL-6 mRNA levels
(iii) ↓ NO secretion
THP-1 [72]
Procyanidin dimer B2: pretreatment for
30 min with 50 μM
(i) ↓ Expression of COX-2
(ii) ↓ Activation of ERK, JNK, and p38 MAPK
(iii) Suppresses NF-κB activation through
stabilization of IκB proteins
Caco-2 IL-1β-stimulated [77]
Polyphenol extract of cocoa (50 μmol of
gallic acid/L); 4 h treatment
(i) In the absence of proinflammatory stimuli, the
polyphenol extract of cocoa induces a basal PGE2
synthesis due to COX-1 induction
(ii) After 24 or 48 h stimulation: it decreased
PGE2 synthesis 4.6- and 2.2-fold, respectively
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(c) Continued.
Anti-inflammatory properties
In vivo/Ex vivo Polyphenol Eﬀect
DSS-induced ulcerative colitis in
Balb/C mice [27]
Cocoa polyphenol-enriched extract
(500mg/kg)
(i) In vivo: ↓ weight loss, improves normal stool
consistency, ↓ visible blood in feces, ↓ neutrophil
infiltration, ↓ NO production, ↓ COX-2
expression, ↓ STAT3 and STAT1α phosphorylation
(ii) Ex vivo in peritoneal macrophages: ↓ IL-6,
IL-1β, and TNF-α
(iii) In vitro in LPS-stimulated RAW 264.7 cells:
inhibits NF-κB
Human PBMCs from 18 healthy
volunteers [78]
Cocoa powder (40 g) with either milk or
water
(i) Cocoa + water:
(a) ↓ NF-κB activation in leukocytes and
adhesion molecules
(b) ↓ sICAM-1
(c)↓ E-selectin
(ii) Cocoa + milk:
(a) no change in NF-κB activation
(b) ↓ sICAM-1
(iii) Milk:
(a) ↑ NF-κB activation
MCF-7 and SKBR3 [87]
(i) After incubation with 250 ng/μL of cocoa extract, 7 genes out of 84 were overexpressed
and 1 was underexpressed in MCF-7 cells, whereas 9 genes were overexpressed in SKBR3
cells
(ii) CYP1A1 mRNA, protein levels, and enzymatic activity increased
(iii) The combination of polyphenol cocoa extract + tamoxifen caused a synergistic
cytotoxicity
RLE cells in vitro and ex vivo [84]
(i) Cocoa polyphenol extracts dose-dependently (10–100 μM) attenuated in vitro
hydrogen peroxide-induced
(a) inhibition of GJIC
(b) phosphorylation and internalization of connexin 43
(c) accumulation of ROS and activation of ERK
(ii) Ex vivo in RLE cell lysates
(a) inhibits hydrogen peroxide-induced MAPK/ MEK1 activity
In vivo
Animals Eﬀects
Wistar Han rats (5 weeks old)
pretreated for 2 weeks with a
cocoa-rich diet and injected with
azoxymethane once a week for 2
weeks [82]
(i) The cocoa-rich diet (1 g of polyphenol/kg of diet):
(a) antiproliferative eﬀects in azoxymethane-induced colon cancer: ↓ ERK, Akt, and
cyclin D1
(b) proapoptotic eﬀects: ↓ Bcl-XL levels and ↑ levels of Bax and caspase-3 activity
(d)
Cancer prevention
In vitro
Cell line Eﬀects
Caco-2 cells [85]
(i) Treatment of cells with 50 μg/mL of procyanidin-enriched extracts:
(a) inhibits cell growth by 70%, blocking the cell cycle in the G2/M phase
(b) ↓ activities of ornithine decarboxylase and S-adenosylmethionine decarboxylase, and
therefore, ↓ the intracellular pool of polyamines
PC12 rat pheochromocytoma
cells [81]
(i) Cocoa procyanidin fraction (1 and 5 μg/mL) and procyanidin B2 (1 and 5 μM):
(a) ↓ cell death attenuating the hydrogen peroxide-induced fragmentation of the nucleus and
DNA
(b) ↓ PARP cleavage, increased Bcl-XL and Bcl-2 expression, and also inhibited activation of
caspase-3 by hydrogen peroxide while attenuating the phosphorylation of JNK and MAPK
HepG2 cells [83]
(i) Pretreatment of cells subjected to oxidative stress with 0.05–50 μg/mL of cocoa polyphenol
extract for 2 or 20 h:
(a) completely prevented cell damage and enhanced the activity of antioxidant enzymes
(b) recovered levels of GSH
(c) prevented in a dose-dependent fashion the increase in ROS
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(d) Continued.
Cancer prevention
In vitro
Salmonella typhimurium strain
TA 98 and TA 102 [86]
(i) Treatment with benzo[a]pyrene
(a) white chocolate did not modulate the number of revertant colonies produced by treatment
(b) milk chocolate and cocoa powder extracts did
(ii) Treatment with t-butyl hydroperoxide
(a) none of the cocoa products tested aﬀected the number of revertant colonies
(b) 13.25mg cocoa powder/mL reduced ethoxyresorufin O-deethylase activity to 17.4%
suggesting that whole cocoa products inhibit CYP1A activity
JB6 P+ cells [88, 89]
(i) Cocoa procyanidin fraction (5 μg/mL) and procyanidin B2 (40 μM) inhibit
(a) TPA-induced neoplastic cell transformation at 47 and 93%, respectively
(b) phosphorylation of MEK, ERK, and p90 ribosomal s6 kinase
(c) COX-2 expression
(d) AP-1 and NF-κB activation, and the TPA induced
(ii) Cocoa polyphenol extract (5–20 μg/mL)
(a) inhibits TNF-α-induced upregulation of VEGF by reducing TNF-α-induced activation of
AP-1 and NF-κB
(b) inhibits TNF-α-induced phosphorylation of Akt and ERK
(c) suppresses PI3K activity by binding PI3K directly
(d) suppresses TNF-α-induced MEK1 activity
MCF-7 and SKBR3 [87]
(i) After incubation with 250 ng/μL of cocoa extract, 7 genes out of 84 were overexpressed and 1
was underexpressed in MCF-7 cells, whereas 9 genes were overexpressed in SKBR3 cells
(ii) CYP1A1 mRNA, protein levels, and enzymatic activity increased
(iii) The combination of polyphenol cocoa extract + tamoxifen caused a synergistic cytotoxicity
RLE cells in vitro and ex vivo [84]
(i) Cocoa polyphenol extracts dose-dependently (10–100 μM) attenuated in vitro hydrogen
peroxide-induced
(a) inhibition of GJIC
(b) phosphorylation and internalization of connexin 43
(c) accumulation of ROS and activation of ERK
(ii) Ex vivo in RLE cell lysates
(a) inhibits hydrogen peroxide-induced MAPK/MEK1 activity
In vivo
Animals Eﬀects
Wistar Han rats (5 weeks old)
pretreated for 2 weeks with a
cocoa-rich diet and injected with
azoxymethane once a week for 2
weeks [82]
(i) The cocoa-rich diet (1 g of polyphenol/kg of diet):
(a) antiproliferative eﬀects in azoxymethane-induced colon cancer: ↓ ERK, Akt, and cyclin D1
(b) proapoptotic eﬀects: ↓ Bcl-XL levels and ↑ levels of Bax and caspase-3 activity
the literature on this subject, Addai [96] established five
possible antimalarial mechanisms for cocoa. Thus, the eﬀects
could be due to the increased availability of antioxidants in
plasma, membrane eﬀects in general and in the erythrocyte
membrane in particular, increased plasma levels of NO,
specific antimalarial activity of cocoa flavanoids and their
derivatives, and enhancement of the immune system medi-
ated by components of cocoa including cocoa polyphenols.
11.5. Eﬀects on Skin Tone and Elasticity. Cocoa polyphenols
have a positive eﬀect on skin structure when applied for at
least 5 days. Studying these eﬀects ex vivo, Gasser et al. [97]
observed that cocoa polyphenols exhibit a positive action
on the parameters assessed, including glycosaminoglycans
and collagens I, III, and IV, associated with skin tone and
elasticity. The doses at which they improve each of these
parameters were determined to be 0.75% and 0.50%.
Mukai et al. [98] studied the suppression by a cocoa
polyphenol extract (100mg/kg, orally) of aryl hydrocarbon
receptor transformation in C57BL/6 mice. Three hours after
administration of the aryl hydrocarbon receptor agonist
3-methylcholanthrene (10mg/kg, i.p.), the cocoa extract
suppressed the induced transformation to control levels by
inhibiting the formation of a heterodimer between the aryl
hydrocarbon receptor and an aryl hydrocarbon receptor
nuclear translocator in the liver. The extract also suppressed
3-methylcholanthrene-induced CYP1A1 expression and
NAD(P)H: quinone-oxidoreductase activity while increasing
glutathione S-transferase activity after 25 h. The authors
concluded that the intake of cocoa polyphenol extract
suppresses the toxicological eﬀects of dioxins in the body
[98]. Moreover, in topical preparations, protect the skin from
oxidative damage caused by ultraviolet (UV) radiation [93].
12. Conclusions
Dark chocolate and cocoa enriched-polyphenol extracts may
be beneficial for human health in diﬀerent ways. Cocoa
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polyphenols have antioxidant properties, which endow them
with various positive eﬀects against several pathological
disorders, including cardiovascular disease, inflammatory
processes, and cancer. Indeed, cocoa polyphenols induce
coronary vasodilatation, increase endothelial NO concen-
trations to induce vascular relaxation, improve vascular
function, and decrease platelet adhesion. Moreover, they
decrease levels of LDL-cholesterol and its oxidation while
increasing HDL-cholesterol. Polyphenols also have anti-
inflammatory activity, especially against IBD, through the
inhibition of diﬀerent transcription factor and cytokines.
These eﬀects also produce chemopreventive eﬀects on other
chronic diseases such as cancer by inhibiting the growth of
various cancer cell lines. Of special interest are the eﬀects of
polyphenols on colon cancer. Indeed, the protective eﬀects of
polyphenols against IBD prevent it from evolving into can-
cer. In addition, it has been demonstrated that polyphenols
cause nonapoptotic cell death, blocking the cell cycle in the
G2/M phase, which potentiates their antiproliferative eﬀects.
To summarize these eﬀects, Table 1 lists the most relevant
studies on cocoa phenolics and their findings, including
the principal eﬀects on metabolism, cardiovascular diseases,
inflammation, and cancer prevention.
Abbreviations, Symbols, and Cell Lines
ABTS: 2, 2′-Azino-bis(3-ethylbenzthiazoline-6-
sulphonic acid)
Akt: Protein kinase B
AhR: Aryl hydrocarbon receptor
AP: Activator protein
Apo: Apolipoprotein
Caco-2: Human epithelial colorectal adenocar-
cinoma cells
CD: Cluster of diﬀerentiation
CD36: Thrombospondin receptor
CD40: TNF receptor superfamily member 5
cGMP: Cyclic guanosine monophosphate
COX: Cyclooxygenase
CYP: Cytochrome P450
DNA: Deoxyribonucleic acid
DPPH: 2,2-Diphenyl-1-pycrylhydrazyl
DSS: Dextran sulfate sodium
EDHF: Endothelium-derived hyperpolarizing factor
eNOS: Endothelial nitric oxide synthase
ER-α: Estrogen receptor-α
ERK: Extracellular signal-regulated protein kinase
FRAP: Ferric reducing-antioxidant power
GJIC: Gap-junction intercellular communication
GM-CSF: Granulocyte macrophage colony-stimulating
factor
HDL: High-density lipoprotein
HepG2: Human hepatocellular carcinoma
IBD: Inflammatory bowel disease
IC50: Inhibitory concentration-50
ICAM: Intercellular adhesion molecule
IFN-γ: Interferon-γ
Ig: Immunoglobulin
IκB: Inhibitor of κB
IL: Interleukin
i.p.: Intraperitoneally
JNK: Jun-terminal kinase
LDL: Low-density lipoprotein
LOX: Lipoxygenase
LPS: Lipopolysaccharide
LT: Leukotrienes
MAPK: Mitogen-activated protein kinase
MCF-7: Breast cancer cells (Michigan Cancer
Foundation-7)
MCP: Monocyte chemoattractant protein
MEK: Mitogen-activated protein kinase kinase
MMP: Matrix metalloproteinase
MPO: Myeloperoxidase
MT1: Membrane type-1
NADPH: Nicotinamide adenine dinucleotide
phosphate
NF-κB: Nuclear factor-κB
NO: Nitric oxide
NOX: NADPH oxidase
PARP: Poly(ADP-ribose)polymerase
PBMCs: Human peripheral blood mononuclear cells
PC12: Rat pheochromocytoma cells
PG: Prostaglandin
PHA: Phytohemagglutinin
PI3 K: Phosphoinositide 3-kinase
PLA2: Phospholipase A2
RNA: Ribonucleic acid
ROS: Reactive oxygen species
RLE: Rat liver epithelial
sICAM: Soluble intercellular adhesion molecule;
CD54
SKBR3: Human breast carcinoma cells
SREBP: Sterol regulatory element binding protein
STAT: Signal transducers and activators of
transcription
sVCAM: Soluble vascular cell adhesion molecule;
CD106
TGF-β1: Transforming growth factor-β1
THP-1: Human monocytic cells
TNF-α: Tumor necrosis factor-α
TPA: 12-O-Tetradecanoylphorbol-13-acetate
UV: Ultraviolet
VEGF: Vascular endothelial growth factor
VLA-4: Very late antigen-4
VSMC: Vascular smooth muscle cell.
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